Barclays PLC Buys 14,027 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Barclays PLC lifted its position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 9.8% during the 4th quarter, HoldingsChannel reports. The firm owned 157,060 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,027 shares during the quarter. Barclays PLC’s holdings in ANI Pharmaceuticals were worth $8,682,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the company. HighTower Advisors LLC purchased a new stake in ANI Pharmaceuticals during the third quarter valued at approximately $222,000. Stifel Financial Corp purchased a new stake in ANI Pharmaceuticals during the 3rd quarter valued at $418,000. Geode Capital Management LLC lifted its position in ANI Pharmaceuticals by 4.2% in the third quarter. Geode Capital Management LLC now owns 425,225 shares of the specialty pharmaceutical company’s stock worth $25,373,000 after buying an additional 17,314 shares during the last quarter. Franklin Resources Inc. boosted its stake in ANI Pharmaceuticals by 6.1% during the third quarter. Franklin Resources Inc. now owns 12,057 shares of the specialty pharmaceutical company’s stock worth $705,000 after buying an additional 691 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in ANI Pharmaceuticals by 6.9% during the third quarter. Principal Financial Group Inc. now owns 89,961 shares of the specialty pharmaceutical company’s stock worth $5,367,000 after buying an additional 5,829 shares during the period. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Down 0.8 %

Shares of ANIP opened at $68.37 on Thursday. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.48. The firm has a market cap of $1.49 billion, a P/E ratio of -124.31 and a beta of 0.49. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock’s 50 day moving average is $63.81 and its two-hundred day moving average is $59.65.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ANIP shares. HC Wainwright reissued a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group initiated coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They issued a “buy” rating and a $80.00 price target on the stock. StockNews.com cut ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 target price on the stock. Finally, Guggenheim reissued a “buy” rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $80.13.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This trade represents a 1.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total transaction of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,200 shares of company stock worth $197,792. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.